Finance

Lists
PVCT:OTCMKTS
Provectus Biopharmaceuticals Inc
0,053 USD
-0,28%
(-0,00015) 1D
6-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PVCT...
Open
0,05 USD
High
0,05 USD
Low
0,05 USD
Mkt. cap
24,24 млн
Avg. vol.
137,54 миң
Volume
33,64 миң
52-wk high
0,08 USD
52-wk low
0,04 USD
EPS
-0,01 USD
Beta
0,91
Shares outstanding
420,28 млн
No. of employees
6
Open
0,05 USD
High
0,05 USD
Low
0,05 USD
Mkt. cap
24,24 млн
Avg. vol.
137,54 миң
Volume
33,64 миң
52-wk high
0,08 USD
52-wk low
0,04 USD
EPS
-0,01 USD
Beta
0,91
Shares outstanding
420,28 млн
No. of employees
6
News stories
From web sources and news partners
About Provectus Biopharmaceuticals Inc
CEO-
Employees6
Founded2002
HeadquartersНоксвилл, Теннесси, Америка Кошмо Штаттары
SectorPharmaceutical industry
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
323,22 миң
248,94 миң
324,27 миң
121,55 миң
Cost of revenue
323,22 миң
248,94 миң
324,27 миң
121,55 миң
Research and development expenses
13,64 миң
13,64 миң
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
831,08 миң
761,24 миң
923,63 миң
737,40 миң
Operating expense
844,72 миң
774,88 миң
923,63 миң
737,40 миң
Total operating expenses
1,17 млн
1,02 млн
1,25 млн
858,95 миң
Operating income
-1,17 млн
-1,02 млн
-1,25 млн
-858,95 миң
Other non operating income
-
-
-
-
EBT including unusual items
-1,32 млн
-1,17 млн
-1,30 млн
-988,72 миң
EBT excluding unusual items
-1,22 млн
-1,07 млн
-1,30 млн
-909,27 миң
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-1,31 млн
-1,17 млн
-1,29 млн
-982,57 миң
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-48,02 миң
-47,32 миң
-53,05 миң
-50,32 миң
Net interest expenses
-48,02 миң
-47,32 миң
-53,05 миң
-50,32 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,17 млн
-1,02 млн
-1,25 млн
-858,48 миң
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору